These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 27927705)

  • 1. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency.
    Niebur HB; Duff CM; Shear GF; Nguyen D; Alberdi TK; Dorsey MJ; Sleasman JW
    Clin Exp Immunol; 2015 Sep; 181(3):441-50. PubMed ID: 25761372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
    Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
    Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push.
    Shapiro R
    Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
    Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M
    J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies.
    Pecoraro A; Ricci S; Vultaggio A; Boggia GM; Spadaro G;
    Clin Drug Investig; 2020 Mar; 40(3):279-286. PubMed ID: 32036588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases.
    Kanegane H; Imai K; Yamada M; Takada H; Ariga T; Bexon M; Rojavin M; Hu W; Kobayashi M; Lawo JP; Nonoyama S; Hara T; Miyawaki T
    J Clin Immunol; 2014 Feb; 34(2):204-11. PubMed ID: 24504846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials.
    Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H
    J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study.
    Borte M; Quinti I; Soresina A; Fernández-Cruz E; Ritchie B; Schmidt DS; McCusker C
    J Clin Immunol; 2011 Dec; 31(6):952-61. PubMed ID: 21932110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis.
    Shapiro RS
    Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
    Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
    Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Subcutaneous immunoglobulin substitution and therapy].
    Gulácsy V; Maródi L
    Orv Hetil; 2011 Jan; 152(2):64-7. PubMed ID: 21177233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency.
    Borte M; Pac M; Serban M; Gonzalez-Quevedo T; Grimbacher B; Jolles S; Zenker O; Neufang-Hueber J; Belohradsky B
    J Clin Immunol; 2011 Oct; 31(5):752-61. PubMed ID: 21674136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS).
    Vultaggio A; Azzari C; Ricci S; Martire B; Palladino V; Gallo V; Pecoraro A; Pignata C; Spadaro G; Graziani S; Moschese V; Trizzino A; Boggia GM; Matucci A
    J Clin Immunol; 2018 Jul; 38(5):602-609. PubMed ID: 29951948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
    Sriaroon P; Ballow M
    Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.